Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 633

1.

Risankizumab versus ustekinumab for plaque psoriasis: a critical appraisal.

Al-Janabi A, Jabbar-Lopez ZK, Griffiths CEM, Yiu ZZN.

Br J Dermatol. 2019 Jan 11. doi: 10.1111/bjd.17624. [Epub ahead of print]

PMID:
30632140
2.

Persistence and Effectiveness of Non-Biologic Systemic Therapies for Moderate-Severe Psoriasis in Adults: a Systematic Review.

Mason KJ, Williams S, Yiu ZZN, McElhone K, Ashcroft DM, Kleyn CE, Jabbar-Lopez ZK, Owen CM, Reynolds NJ, Smith CH, Wilson N, Warren RB, Griffiths CEM.

Br J Dermatol. 2019 Jan 10. doi: 10.1111/bjd.17625. [Epub ahead of print] Review.

PMID:
30628069
3.

HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis.

Dand N, Duckworth M, Baudry D, Russell A, Curtis CJ, Lee SH, Evans I, Mason KJ, Alsharqi A, Becher G, Burden AD, Goodwin RG, McKenna K, Murphy R, Perera GK, Rotarescu R, Wahie S, Wright A, Reynolds NJ, Warren RB, Griffiths CEM, Smith CH, Simpson MA, Barker JN; BADBIR study group, the BSTOP study group and the PSORT consortium.

J Allergy Clin Immunol. 2018 Dec 19. pii: S0091-6749(18)32780-5. doi: 10.1016/j.jaci.2018.11.038. [Epub ahead of print]

PMID:
30578879
4.

Selective proteolysis by matrix metalloproteinases of photo-oxidised dermal extracellular matrix proteins.

Hibbert SA, Watson REB, Griffiths CEM, Gibbs NK, Sherratt MJ.

Cell Signal. 2019 Feb;54:191-199. doi: 10.1016/j.cellsig.2018.11.024. Epub 2018 Dec 3.

5.

Burden of suicide presented as one of the leading causes of death: uncover facts or misrepresent statistics?

Gjertsen F, Bruzzone S, Griffiths CE.

J Glob Health. 2019 Jun;9(1):010401. doi: 10.7189/jogh.09.010401.

6.

Development and validation of a multivariable risk prediction model for serious infection in patients with psoriasis receiving systemic therapy.

Yiu ZZN, Sorbe C, Lunt M, Rustenbach SJ, Kühl L, Augustin M, Mason KJ, Ashcroft DM, Griffiths CEM, Warren RB; BADBIR Study Group.

Br J Dermatol. 2018 Nov 15. doi: 10.1111/bjd.17421. [Epub ahead of print]

PMID:
30430546
7.

Aging in Skin of Color: Disruption to Elastic Fiber Organization Is Detrimental to Skin's Biomechanical Function.

Langton AK, Alessi S, Hann M, Chien AL, Kang S, Griffiths CEM, Watson REB.

J Invest Dermatol. 2018 Nov 4. pii: S0022-202X(18)32790-8. doi: 10.1016/j.jid.2018.10.026. [Epub ahead of print]

PMID:
30404021
8.

Aged human skin accumulates mast cells with altered functionality that localize to macrophages and vasoactive intestinal peptide-positive nerve fibres.

Pilkington SM, Barron MJ, Watson REB, Griffiths CEM, Bulfone-Paus S.

Br J Dermatol. 2018 Oct 6. doi: 10.1111/bjd.17268. [Epub ahead of print]

PMID:
30291626
9.

A small population, randomised, placebo-controlled trial to determine the efficacy of anakinra in the treatment of pustular psoriasis: study protocol for the APRICOT trial.

Cornelius V, Wilson R, Cro S, Barker J, Burden D, Griffiths CEM, Lachmann H, McAteer H, Reynolds N, Pink A, Warren RB, Capon F, Smith C.

Trials. 2018 Aug 29;19(1):465. doi: 10.1186/s13063-018-2841-y.

10.

Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study.

Warren RB, Marsden A, Tomenson B, Mason KJ, Soliman MM, Burden AD, Reynolds NJ, Stocken D, Emsley R, Griffiths CEM, Smith C; PSORT Consortium and on behalf of the BADBIR Study Group.

Br J Dermatol. 2018 Aug 28. doi: 10.1111/bjd.16776. [Epub ahead of print]

PMID:
30155885
11.

Defining the Therapeutic Range for Adalimumab and Predicting Response in Psoriasis: A Multicenter Prospective Observational Cohort Study.

Wilkinson N, Tsakok T, Dand N, Bloem K, Duckworth M, Baudry D, Pushpa-Rajah A, Griffiths CEM, Reynolds NJ, Barker J, Warren RB, Burden AD, Rispens T, Stocken D, Smith C; BSTOP study group; PSORT consortium.

J Invest Dermatol. 2019 Jan;139(1):115-123. doi: 10.1016/j.jid.2018.07.028. Epub 2018 Aug 18.

12.

Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years.

Griffiths CEM, Papp KA, Kimball AB, Randazzo B, Song M, Li S, Shen YK, Blauvelt A.

J Drugs Dermatol. 2018 Aug 1;17(8):826-832.

PMID:
30124721
13.

Generating EQ-5D-3L Utility Scores from the Dermatology Life Quality Index: A Mapping Study in Patients with Psoriasis.

Davison NJ, Thompson AJ, Turner AJ, Longworth L, McElhone K, Griffiths CEM, Payne K; BADBIR Study Group.

Value Health. 2018 Aug;21(8):1010-1018. doi: 10.1016/j.jval.2017.10.024. Epub 2017 Dec 26.

PMID:
30098665
14.

Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR).

Yiu ZZN, Ashcroft DM, Evans I, McElhone K, Lunt M, Smith CH, Walton S, Murphy R, Reynolds NJ, Ormerod AD, Griffiths CEM, Warren RB; BADBIR Study Group.

Br J Dermatol. 2018 Aug 2. doi: 10.1111/bjd.17036. [Epub ahead of print]

PMID:
30070708
15.

Clinical and genetic differences between pustular psoriasis subtypes.

Twelves S, Mostafa A, Dand N, Burri E, Farkas K, Wilson R, Cooper HL, Irvine AD, Oon HH, Kingo K, Köks S, Mrowietz U, Puig L, Reynolds N, Tan ES, Tanew A, Torz K, Trattner H, Valentine M, Wahie S, Warren RB, Wright A, Bata-Csörgő Z, Szell M, Griffiths CEM, Burden AD, Choon SE, Smith CH, Barker JN, Navarini AA, Capon F.

J Allergy Clin Immunol. 2018 Jul 21. pii: S0091-6749(18)31039-X. doi: 10.1016/j.jaci.2018.06.038. [Epub ahead of print]

16.

A Framework for Multi-Omic Prediction of Treatment Response to Biologic Therapy for Psoriasis.

Foulkes AC, Watson DS, Carr DF, Kenny JG, Slidel T, Parslew R, Pirmohamed M; PSORT Consortium, Anders S, Reynolds NJ, Griffiths CEM, Warren RB, Barnes MR.

J Invest Dermatol. 2019 Jan;139(1):100-107. doi: 10.1016/j.jid.2018.04.041. Epub 2018 Jul 17.

PMID:
30030151
17.

Psychiatric morbidity and suicidal behaviour in psoriasis: a primary care cohort study.

Parisi R, Webb RT, Kleyn CE, Carr MJ, Kapur N, Griffiths CEM, Ashcroft DM.

Br J Dermatol. 2019 Jan;180(1):108-115. doi: 10.1111/bjd.17004. Epub 2018 Oct 10.

PMID:
30007069
18.

Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study.

Paul C, Griffiths CEM, van de Kerkhof PCM, Puig L, Dutronc Y, Henneges C, Dossenbach M, Hollister K, Reich K.

J Am Acad Dermatol. 2019 Jan;80(1):70-79.e3. doi: 10.1016/j.jaad.2018.06.039. Epub 2018 Jun 30.

PMID:
29969700
19.

Greater improvement in quality of life outcomes in patients using fixed-combination calcipotriol plus betamethasone dipropionate aerosol foam versus gel: results from the PSO-ABLE study.

Griffiths CE, Stein Gold L, Cambazard F, Kalb RE, Lowson D, Møller A, Paul C.

Eur J Dermatol. 2018 Jun 1;28(3):356-363. doi: 10.1684/ejd.2018.3302.

PMID:
29952297
20.

Keratinocytes derived from late-onset-psoriasis skin do not impair Langerhans cell migration.

Eaton LH, Dearman RJ, Kimber I, Griffiths CEM.

Br J Dermatol. 2018 Nov;179(5):1208-1209. doi: 10.1111/bjd.16896. Epub 2018 Sep 25. No abstract available.

PMID:
29923325
21.

What's new in psoriasis treatment? An analysis of systematic reviews published in 2015.

Foulkes AC, Ferguson F, Grindlay DJC, Williams HC, Griffiths CEM, Warren RB.

Clin Exp Dermatol. 2018 Oct;43(7):759-765. doi: 10.1111/ced.13601. Epub 2018 May 27. Review.

PMID:
29806111
22.

Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials.

Foley P, Gordon K, Griffiths CEM, Wasfi Y, Randazzo B, Song M, Li S, Shen YK, Blauvelt A.

JAMA Dermatol. 2018 Jun 1;154(6):676-683. doi: 10.1001/jamadermatol.2018.0793.

23.

Langerhans cells express human β-defensin 3: relevance for immunity during skin ageing.

Pilkington SM, Dearman RJ, Kimber I, Griffiths CEM.

Br J Dermatol. 2018 Nov;179(5):1170-1171. doi: 10.1111/bjd.16770. Epub 2018 Sep 12. No abstract available.

PMID:
29758092
24.

Cumulative exposure to biological therapy and risk of cancer in patients with psoriasis: a meta-analysis of Psonet studies from Israel, Italy, Spain, the U.K. and Republic of Ireland.

Garcia-Doval I, Descalzo MA, Mason KJ, Cohen AD, Ormerod AD, Gómez-García FJ, Cazzaniga S, Feldhamer I, Ali H, Herrera-Acosta E, Griffiths CEM, Stern RS, Naldi L; Psonet Network.

Br J Dermatol. 2018 Oct;179(4):863-871. doi: 10.1111/bjd.16715. Epub 2018 Jul 24.

PMID:
29723914
25.

Lipidomics for translational skin research: A primer for the uninitiated.

Kendall AC, Koszyczarek MM, Jones EA, Hart PJ, Towers M, Griffiths CEM, Morris M, Nicolaou A.

Exp Dermatol. 2018 Jul;27(7):721-728. doi: 10.1111/exd.13558. Epub 2018 May 7. Review.

PMID:
29654617
26.

Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial.

Papp KA, Merola JF, Gottlieb AB, Griffiths CEM, Cross N, Peterson L, Cioffi C, Blauvelt A.

J Am Acad Dermatol. 2018 Aug;79(2):277-286.e10. doi: 10.1016/j.jaad.2018.03.037. Epub 2018 Mar 30.

27.

Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3).

Blauvelt A, Papp KA, Griffiths CEM, Puig L, Weisman J, Dutronc Y, Kerr LF, Ilo D, Mallbris L, Augustin M.

Am J Clin Dermatol. 2018 Jun;19(3):457. doi: 10.1007/s40257-018-0353-x.

28.

Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR.

Mason KJ, Barker JNWN, Smith CH, Hampton PJ, Lunt M, McElhone K, Warren RB, Yiu ZZN, Griffiths CEM, Burden AD; BADBIR Study Group.

JAMA Dermatol. 2018 May 1;154(5):581-588. doi: 10.1001/jamadermatol.2018.0183.

PMID:
29590279
29.

Patient-dermatologist agreement in psoriasis severity, symptoms and satisfaction: results from a real-world multinational survey.

Griffiths CEM, Augustin M, Naldi L, Romiti R, Guevara-Sangines E, Howe T, Pietri G, Gilloteau I, Richardson C, Tian H, Jo SJ.

J Eur Acad Dermatol Venereol. 2018 Sep;32(9):1523-1529. doi: 10.1111/jdv.14937. Epub 2018 Jul 13.

PMID:
29524271
30.

Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial.

Papp KA, Blauvelt A, Kimball AB, Han C, Randazzo B, Wasfi Y, Shen YK, Li S, Griffiths CEM.

J Eur Acad Dermatol Venereol. 2018 Sep;32(9):1515-1522. doi: 10.1111/jdv.14910. Epub 2018 Apr 10.

31.

Structural and compositional diversity of fibrillin microfibrils in human tissues.

Eckersley A, Mellody KT, Pilkington S, Griffiths CEM, Watson REB, O'Cualain R, Baldock C, Knight D, Sherratt MJ.

J Biol Chem. 2018 Apr 6;293(14):5117-5133. doi: 10.1074/jbc.RA117.001483. Epub 2018 Feb 16.

32.

Acute psychosocial stress downregulates N-methyl-d-aspartate receptors in healthy human skin.

Hunter HJA, Morsman E, Mellody KT, Ogden SK, Zeef LAH, Hayes A, Griffiths CEM, Kleyn CE.

Br J Dermatol. 2018 Jun;178(6):1458-1459. doi: 10.1111/bjd.16466. Epub 2018 May 9. No abstract available.

PMID:
29451693
33.

Does message framing affect changes in behavioural intentions in people with psoriasis? A randomized exploratory study examining health risk communication.

Keyworth C, Nelson PA, Bundy C, Pye SR, Griffiths CEM, Cordingley L.

Psychol Health Med. 2018 Aug;23(7):763-778. doi: 10.1080/13548506.2018.1427876. Epub 2018 Jan 30.

PMID:
29380626
34.

Differential effects of secukinumab vs. ustekinumab for treatment of psoriasis on quality of life, work productivity and activity impairment: a structural equation modelling analysis.

Stull DE, Griffiths CEM, Gilloteau I, Zhao Y, Guana A, Finlay AY, Sherif B, Houghton K, Puig L.

Br J Dermatol. 2018 Jun;178(6):1297-1307. doi: 10.1111/bjd.16366. Epub 2018 Apr 14.

PMID:
29355896
35.

A photonumeric scale for the assessment of atrophic facial photodamage.

Ayer J, Ahmed A, Duncan-Parry E, Beck P, Griffiths TW, Watson REB, Griffiths CEM.

Br J Dermatol. 2018 May;178(5):1190-1195. doi: 10.1111/bjd.16331. Epub 2018 Mar 30.

PMID:
29333668
36.

A multidimensional assessment of the burden of psoriasis: results from a multinational dermatologist and patient survey.

Griffiths CEM, Jo SJ, Naldi L, Romiti R, Guevara-Sangines E, Howe T, Pietri G, Gilloteau I, Richardson C, Tian H, Augustin M.

Br J Dermatol. 2018 Jul;179(1):173-181. doi: 10.1111/bjd.16332. Epub 2018 Apr 24.

PMID:
29328510
37.

Defining tissue proteomes by systematic literature review.

Hibbert SA, Ozols M, Griffiths CEM, Watson REB, Bell M, Sherratt MJ.

Sci Rep. 2018 Jan 11;8(1):546. doi: 10.1038/s41598-017-18699-8.

38.

Impaired Langerhans cell migration in psoriasis is due to an altered keratinocyte phenotype induced by interleukin-17.

Eaton LH, Mellody KT, Pilkington SM, Dearman RJ, Kimber I, Griffiths CEM.

Br J Dermatol. 2018 Jun;178(6):1364-1372. doi: 10.1111/bjd.16172. Epub 2018 Mar 31.

PMID:
29194565
39.

Intentional and Unintentional Medication Non-Adherence in Psoriasis: The Role of Patients' Medication Beliefs and Habit Strength.

Thorneloe RJ, Griffiths CEM, Emsley R, Ashcroft DM, Cordingley L; British Association of Dermatologists Biologic Interventions Register; Psoriasis Stratification to Optimise Relevant Therapy Study Groups.

J Invest Dermatol. 2018 Apr;138(4):785-794. doi: 10.1016/j.jid.2017.11.015. Epub 2017 Nov 26.

40.

Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).

Iskandar IYK, Warren RB, Lunt M, Mason KJ, Evans I, McElhone K, Smith CH, Reynolds NJ, Ashcroft DM, Griffiths CEM; BADBIR Study Group.

J Invest Dermatol. 2018 Apr;138(4):775-784. doi: 10.1016/j.jid.2017.09.044. Epub 2017 Dec 6.

41.

The role of the microbiome in psoriasis: moving from disease description to treatment selection?

Langan EA, Griffiths CEM, Solbach W, Knobloch JK, Zillikens D, Thaçi D.

Br J Dermatol. 2018 May;178(5):1020-1027. doi: 10.1111/bjd.16081. Epub 2018 Mar 6. Review.

PMID:
29071712
42.

Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).

Yiu ZZN, Smith CH, Ashcroft DM, Lunt M, Walton S, Murphy R, Reynolds NJ, Ormerod AD, Griffiths CEM, Warren RB; BADBIR Study Group.

J Invest Dermatol. 2018 Mar;138(3):534-541. doi: 10.1016/j.jid.2017.10.005. Epub 2017 Oct 17.

43.

Feeding filaggrin: effects of l-histidine supplementation in atopic dermatitis.

Tan SP, Brown SB, Griffiths CE, Weller RB, Gibbs NK.

Clin Cosmet Investig Dermatol. 2017 Oct 5;10:403-411. doi: 10.2147/CCID.S146760. eCollection 2017.

44.

Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3).

Papp KA, Leonardi CL, Blauvelt A, Reich K, Korman NJ, Ohtsuki M, Paul C, Ball S, Cameron GS, Erickson J, Zhang L, Mallbris L, Griffiths CEM.

Br J Dermatol. 2018 Mar;178(3):674-681. doi: 10.1111/bjd.16050. Epub 2018 Feb 23.

PMID:
28991370
45.

Reply to 'Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials': reply from the authors.

Rungapiromnan W, Yiu ZZN, Warren RB, Griffiths CEM, Ashcroft DM.

Br J Dermatol. 2017 Dec;177(6):1766-1767. doi: 10.1111/bjd.16043. Epub 2017 Nov 22. No abstract available.

PMID:
28990164
46.

Exome-wide association study reveals novel psoriasis susceptibility locus at TNFSF15 and rare protective alleles in genes contributing to type I IFN signalling.

Dand N, Mucha S, Tsoi LC, Mahil SK, Stuart PE, Arnold A, Baurecht H, Burden AD, Callis Duffin K, Chandran V, Curtis CJ, Das S, Ellinghaus D, Ellinghaus E, Enerback C, Esko T, Gladman DD, Griffiths CEM, Gudjonsson JE, Hoffman P, Homuth G, Hüffmeier U, Krueger GG, Laudes M, Lee SH, Lieb W, Lim HW, Löhr S, Mrowietz U, Müller-Nurayid M, Nöthen M, Peters A, Rahman P, Reis A, Reynolds NJ, Rodriguez E, Schmidt CO, Spain SL, Strauch K, Tejasvi T, Voorhees JJ, Warren RB, Weichenthal M, Weidinger S, Zawistowski M, Nair RP, Capon F, Smith CH, Trembath RC, Abecasis GR, Elder JT, Franke A, Simpson MA, Barker JN.

Hum Mol Genet. 2017 Nov 1;26(21):4301-4313. doi: 10.1093/hmg/ddx328.

47.

Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study.

Gerdes S, Thaçi D, Griffiths CEM, Arenberger P, Poetzl J, Wuerth G, Afonso M, Woehling H.

J Eur Acad Dermatol Venereol. 2018 Mar;32(3):420-427. doi: 10.1111/jdv.14605. Epub 2017 Nov 2.

48.

Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies.

Gordon KB, Blauvelt A, Foley P, Song M, Wasfi Y, Randazzo B, Shen YK, You Y, Griffiths CEM.

Br J Dermatol. 2018 Jan;178(1):132-139. doi: 10.1111/bjd.16008. Epub 2017 Dec 14.

PMID:
28940259
49.

Alcohol-Related Mortality in Patients With Psoriasis: A Population-Based Cohort Study.

Parisi R, Webb RT, Carr MJ, Moriarty KJ, Kleyn CE, Griffiths CEM, Ashcroft DM.

JAMA Dermatol. 2017 Dec 1;153(12):1256-1262. doi: 10.1001/jamadermatol.2017.3225.

50.

Developing a protocol to identify and prioritize research questions for psoriasis: a James Lind Alliance Priority Setting Partnership.

Majeed-Ariss R, McPhee M, Bundy C, Griffiths CEM, Young H; Psoriasis Priority Setting Partnership Steering Group.

Br J Dermatol. 2018 Jun;178(6):1383-1387. doi: 10.1111/bjd.15992. Epub 2018 Mar 31.

PMID:
28906549

Supplemental Content

Loading ...
Support Center